A national diagnostics and pathology lab chain offering clinical testing and preventive health screening across India.
lalpathlabs.comFounded
1949
Industry
Diagnostics and pathology laboratory services
Headquarters
Gurugram, Haryana (corporate office)
Employees
1,001 to 5,000
Revenue (FY26)
INR 2,763 croreMarket Cap
INR 28,471 croreListed on
NSE: LALPATHLAB / BSE: 539524
CEO
Shankha Banerjee
Chairman
Arvind Lal (Executive Chairman)
Legal name
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited is an Indian diagnostics and pathology-lab chain. The business traces back to 1949, and the present company was incorporated in 1995 (CIN L74899DL1995PLC065388). It runs a national reference laboratory and a pan-India network of laboratories, diagnostic centres, and collection points that offer blood tests, urine analysis, specialised infection testing, and preventive health screenings.
The company is publicly listed on the National Stock Exchange (LALPATHLAB) and the Bombay Stock Exchange (539524), following its 2015 IPO. For the fiscal year ended March 2026 it reported revenue of about INR 2,763 crore, and its market capitalisation was around INR 28,471 crore as of July 2026. It operates branded health packages and offerings including Swasthfit, OncoPro, and NephroPro, and has grown through acquisitions such as Suburban Diagnostics.
Leadership is anchored by Executive Chairman Arvind Lal, with Shankha Banerjee serving as Chief Executive Officer since May 2024 and Ved Prakash Goel as Group CEO and Chief Financial Officer. Vandana Lal is a Whole-Time Director. The corporate headquarters is in Gurugram, Haryana, with the registered office in Rohini, New Delhi, and LinkedIn lists the company in the 1,001 to 5,000 employee band.
Executive Chairman
Chief Executive Officer
Group CEO & Chief Financial Officer
Whole-Time Director
Interview experience
Favourable
Interview difficulty
Medium
Interview process length
About a day or two
Practice real questions and get instant feedback before the big day.
Q: What is the correct order of draw for blood collection?
A: The standard order is blood culture bottles first, then the light blue coagulation tube, the red or gold serum tube, the green heparin tube, the lavender EDTA tube, and finally the grey fluoride tube. Following this order prevents additive carryover between tubes.
Q: What is the full form of EDTA?
A: EDTA stands for Ethylenediaminetetraacetic acid. It's an anticoagulant used in lavender-top tubes that binds calcium to stop the blood from clotting, which keeps cells intact for haematology tests.
Q: Which tube is used to collect a D-dimer sample?
A: A D-dimer sample is collected in the light blue sodium citrate tube, the same coagulation tube used for PT and APTT. The 9 to 1 blood-to-citrate ratio must be kept for an accurate result.
Q: What does QC stand for, and what does it cover?
A: QC stands for Quality Control. It covers running known control samples, checking equipment calibration, and reviewing results against expected ranges so patient results stay reliable.
Practice real questions and get instant feedback before the big day.
Reported average
₹19,865/month
8 Salaries submitted
Reported average
₹16,837/month
5 Salaries submitted
Reported average
₹23,924/month
8 Salaries submitted
Reported average
₹23,244/month
3 Salaries submitted
Reported average
₹4,06,027/year
2 Salaries submitted
Reported average
₹12,257/month
2 Salaries submitted
Compare pay across roles and see where you stand before you negotiate.
Patiala, Punjab • Full-time
₹6,00,000/year
Ahmedabad, Gujarat • Full-time
₹6,00,000/year
Mumbai, Maharashtra • Full-time
₹6,00,000/year
Delhi • Full-time
Delhi • Full-time
Panipat, Haryana • Full-time
Tailor your resume to each Dr Lal PathLabs role in minutes.
June 29, 2026
Board to review Q1 FY27 results on July 24, 2026
Dr Lal PathLabs scheduled a board meeting for July 24, 2026 to consider unaudited results for the first quarter of fiscal 2026-27. The update came after a strong prior quarter that saw profit growth of around 49 percent.
#earnings #Q1FY27 #boardmeeting
View postJune 16, 2026
Dr Lal PathLabs sets up wholly owned Dubai subsidiary for overseas push
The company received its incorporation certificate for DR LAL PATHLABS FZCO in the Dubai Multi Commodities Centre on June 12, 2026, backing it with about AED 1.91 crore (roughly ₹43.8 crore) to explore diagnostics acquisitions, tie-ups and joint ventures in the region. The stock jumped sharply on the news.
#internationalexpansion #dubai #diagnostics
View postApril 30, 2026
FY26 revenue reaches ₹2,762.90 crore, PAT ₹509.80 crore
For the year ended March 31, 2026 the company posted consolidated revenue of ₹2,762.90 crore and profit after tax of ₹509.80 crore, with Q4 revenue of ₹702.70 crore. The board also proposed a final dividend of ₹4 per share for approval at the July 25 AGM.
#FY26results #revenuegrowth #dividend
View postApril 30, 2026
Dr Lal PathLabs to acquire Shahbazkers Diagnostic Centre in Mumbai
The board approved buying 100 percent of Shahbazkers Diagnostic Centre Private Limited for up to ₹20 crore, expected to close by May 31, 2026. The Mumbai lab carries a 45-year legacy and strengthens the company's footprint in Maharashtra.
#acquisition #maharashtra #expansion
View postApril 30, 2026
Q4 FY26 revenue up 16.6% as network and preventive health grow
Q4 revenue rose 16.6 percent year on year on 12.9 percent sample-volume growth, and the company added 14 new labs and over 1,100 collection centers during the year. Its Swasthfit preventive-health brand contributed about 27 percent of FY26 revenue.
#Q4FY26 #Swasthfit #networkexpansion
View postDr Lal PathLabs is an Indian diagnostics and pathology-lab chain. It runs a national reference laboratory and a pan-India network of labs and collection points offering blood tests, urine analysis, specialised testing, and preventive health screening.
